Insulet Omnipod
As reported in August 2022 by MedTechDive,The Omnipod 5 is one of two insulin pumps manufactured by the company that can be purchased through pharmacies, which Insulet said removes the high-upfront cost and four-year lock-in period associated with sales through durable medical equipment sellers. In a June investor event, the company’s leaders said that they expect the new device will increase the number of new clients won away from competitors. Currently, about 20% of sales come from users who switch from competing devices.
Insulet will report its second quarter earnings results on Thursday afternoon. Analysts are watching for more information on the integration of the Omnipod 5 with Abbott Laboratories’ and Dexcom’s newest CGMs, as well as clearance in Europe and a clinical trial of the device in patients with Type 2 diabetes.
To read more, CLICK HERE.
